EQUITY RESEARCH - RESULTS FLASH



BCH TB



BANGKOK CHAIN HOSPITAL

THAILAND / HEALTH CARE SERVICES

BUY

THB17.20

2Q25 results at first glance

กำไรสุทธิ 2Q25 แข็งแกร่ง (+21% q-q, +40% y-y) สูงกว่าประมาณการของเรา 12% และสูงกว่า Consensus คาด 16%

Highlights

- BCH รายงานกำไรสุทธิ 2Q25 แข็งแกร่งที่ 388 ล้านบาท (+21% q-q, +40% y-y) สูงกว่า ประมาณการของเรา 12% และสูงกว่า Consensus คาด 16% จากอัตรากำไรขั้นตันที่ ดีกว่าคาด 2ppts
- รายได้รวมเพิ่มขึ้น 4% q-q (+6% y-y) เป็น 3.02 พันลบ. จากผู้ป่วยในประเทศ โดยมี จำนวนผู้ป่วยไข้หวัดใหญ่และโควิด-19 เพิ่มขึ้นในไตรมาสนี้ ขณะที่ผู้ป่วยต่างประเทศ กลับมาฟื้นตัว โดยเฉพาะจากตะวันออกกลางหลังเทศกาลรอมฎอน รายได้ OPD (คิดเป็น 36% ของรายได้) เพิ่มขึ้น 4% q-q และ 2% y-y
- รายได้คนไข้ประกันสังคม (สัดส่วน 37% ของรายได้) เพิ่มขึ้น 9% q-q และ 17% y-y ได้ แรงหนุนจากการจ่ายค่ารักษาพยาบาล high-cost care กลับมาที่อัตราปกติ 12,000 บาท/RW (2Q24: 7,200 บาท/RW)
- อัตรา EBITDA margin ขยายตัว 1 จุด q-q (+4 จุด y-y) เป็น 26% จากการบริหารตันทุน อย่างมีประสิทธิภาพ เช่น ค่าบุคลากร เวชภัณฑ์ และการจัดจำหน่าย รวมถึงมาร์จิ้นที่ แข็งแกร่งขึ้นจากกลุ่มคนไข้ประกันสังคม
- หากไม่รวมการตัดจำหน่ายรายได้จากกลุ่มคนไข้ประกันสังคม ใน 2Q24 กำไรปกติ 2Q25
 ยังเติบโตแข็งแกร่ง 13% y-y

Outlook

- กำไรสุทธิ 1H25 อยู่ที่ 710 ล้านบาท (+19% y-y) คิดเป็น 48% ของประมาณการทั้งปีของ เรา
- คาดว่ากำไร 2H25 จะสูงกว่า 1H25 ตามฤดูกาล ปริมาณผู้ป่วยต่างประเทศอาจฟื้นตัว ต่อเนื่องในช่วงครึ่งปีหลัง และการจ่ายค่ารักษาพยาบาล high-cost care ที่กลับสู่อัตรา ปกติใน 4Q25 จะหนุนการเติบโต y-y
- การประเมินมูลค่าหุ้นยังถือว่าถูก ซื้อขายที่ P/E ปี 2026E 22 เท่า หรือ -0.5SD จาก ค่าเฉลี่ยการซื้อขายย้อนหลัง 10 ปี

CLOSE THB14.10 UP/DOWNSIDE +22.0% TP vs CONSENSUS -1.9%

TARGET PRICE

KEY STOCK DATA

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	11,725	12,473	13,227	13,942
Net profit	1,282	1,483	1,581	1,654
EPS (THB)	0.51	0.59	0.63	0.66
vs Consensus (%)	-	(4.2)	(8.2)	(10.3)
EBITDA	2,602	3,031	3,241	3,444
Recurring net profit	1,200	1,483	1,581	1,654
Core EPS (THB)	0.48	0.59	0.63	0.66
EPS growth (%)	(14.7)	23.6	6.6	4.6
Core P/E (x)	29.3	23.7	22.2	21.3
Dividend yield (%)	3.5	2.8	2.8	2.7
EV/EBITDA (x)	13.7	11.7	10.9	10.2
Price/book (x)	2.7	2.6	2.5	2.4
Net debt/Equity (%)	(3.5)	(6.0)	(6.1)	(7.3)
ROE (%)	9.4	11.2	11.5	11.5



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	4.4	(7.2)	(7.8)
Relative to country (%)	(4.3)	(12.5)	(6.2)
Mkt cap (USD m)			1,086
3m avg. daily turnover (USD m)			2.5
Free float (%)			50
Major shareholder	Chaler	m Harnpha	nich (33%)
12m high/low (THB)		1	9.20/12.30
Issued shares (m)			2,493.75

Sources: Bloomberg consensus; FSSIA estimates



Vatcharut Vacharawongsith

Fundamental Investment Analyst on Securities; License no. 018301 vatcharut.v@fssia.com, +66 2646 9969

Bangkok Chain Hospital BCH TB Vatcharut Vacharawongsith

Exhibit 1: BCH - 2Q25 results summary

	2Q24	3Q24	4Q24	1Q25	2Q25	Cha	nge	1H24	1H25	Chg.	2025E	Chg.
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	(THB m)	(y-y %)				
Sales	2,857	3,261	2,763	2,903	3,020	4	6	5,701	5,923	4	12,473	6
COGS (incl. depreciation)	(2,112)	(2,238)	(2,133)	(2,088)	(2,112)	1	(0)	(4,156)	(4,199)	1	(8,879)	4
Gross profit	744	1,023	630	815	909	11	22	1,545	1,724	12	3,594	12
SG&A	(388)	(417)	(414)	(376)	(402)	7	4	(764)	(777)	2	(1,646)	3
Operating profit	356	607	216	440	507	15	42	781	946	21	1,948	21
Net other income	28	24	45	27	29	8	4	51	57	10	120	(1)
Interest expense	(13)	(15)	(15)	(15)	(14)	(5)	13	(24)	(29)	23	(55)	0
Pretax profit	372	615	246	452	522	16	40	808	974	20	2,013	21
Income Tax	(70)	(122)	(48)	(98)	(118)	19	69	(157)	(216)	38	(403)	16
Associates	(0)	(0)	(0)	1	0			0	1	2,925	(1)	0
Minority interest	(25)	(40)	(27)	(26)	(23)	(9)	(6)	(56)	(49)	(12)	(127)	3
Core profit	277	453	171	328	381	16	38	596	709	19	1,483	24
Extraordinaries, GW & FX	0	0	62	(7)	7			0	0			
Reported net profit	277	453	233	321	388	21	40	596	710	19	1,483	24
Outstanding shares (m)	2,494	2,494	2,494	2,494	2,494	0	0	2,494	2,494	0	2,494	0
Core EPS (THB)	0.11	0.18	0.09	0.13	0.16	21	40	0.24	0.28	19	0.59	24
EPS (THB)	0.11	0.18	0.09	0.13	0.16	21	40	0.24	0.28	19	0.59	24
COGS (excl. depreciation)	1,871	1,987	1,868	1,830	1,851	1	(1)	3,674	3,681	96	7,796	4
Depreciation	242	251	265	258	260	1	8	482	518	11	1,083	9
EBITDA	626	882	527	725	796	10	27	1,314	1,521	89	3,151	16
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	(%)	(ppt)
Gross margin	26	31	23	28	30	2	4	27	29.1	2	29	2
SG&A/Revenue	13.6	12.8	15.0	12.9	13	0	(0)	13	13.1	(0)	13	(0)
EBITDA margin	22	27	19	25	26	1	4	23	25.7	3	24	2
Net profit margin	10	14	8	11	13	2	3	10	12.0	2	12	2

Sources: BCH; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Profit series Profit serie	Bangkek Gham Hoopka					
Case profit 1,816 1,816 1,817 1,918 1,919 1,918 1,919 1,918 1,919 1,918 1,919 1,918 1,919 1,918 1,919 1,918	Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Gross profit 3,613 3,199 3,594 3,907 3,090 Oberating piacone - <t< td=""><td>Revenue</td><td>11,729</td><td>11,725</td><td>12,473</td><td>13,227</td><td>13,942</td></t<>	Revenue	11,729	11,725	12,473	13,227	13,942
Comparing piss 1,75 1,5 1,55 1,5 1,55 1,5 1,5 1,5 1,5 1,5 1,5 1,5 1,5 1,5 1,5	Cost of goods sold	(8,116)	(8,527)	(8,879)	(9,420)	(9,952)
Caparaing Costis 1,755 1,565 1,666 1,733 1,814 3,444 3,444 3,646 1,666	Gross profit	3,613	3,199	3,594	3,807	3,990
Depending BHTDA	-	-	-	-	-	-
Poperating PBIT				, ,		
Cookering EBT						
Operating EBIT 1,859 1,604 1,948 2,074 2,177 Net Inancing costs 1,77 (41) (40)	•	(944)	(998)	(1,083)	(1,167)	(1,266)
Net financing costs		4.050	-	-	- 0.074	- 0.477
Associates			•	•	•	
Reauring non-operating income 102 106 111 116 122 Non-recurring items 0 92 0 0 0 Tax (405) (346) (403) (430) (430) Tax (405) (346) (403) (430) (430) Profit after tax (1,479) 1,405 1,610 1,720 1,833 Minority interests (73) (123) (127) (139) (153) Preferred dividends 1 -	•					. ,
Non-recurring items						
Profit before tax						
Tax (4405) (346) 4(30) (430) 4(38) Profit after tax 1,479 1,405 1,610 1,720 1,808 Minority interests (73) 1,123 (127) (139) (153) Prefered dividends 1 1 1 1 1 1 Reported net profit 1,406 1,202 1,433 1,581 1,684 Reported net profit 1,406 1,202 1,433 1,581 1,684 Reported pet profit 1,406 1,202 1,433 1,581 1,685 Reported pet profit 1,406 1,202 1,433 1,581 1,685 Reported EPS 0.56 0,48 0,59 0,63 0,66 Reported EPS 0.56 0,48 0,59 0,63 0,66 DPS 0.50 0,50 0,40 0,40 0,38 DPS 0.50 0,50 0,40 0,44 0,44 CPerating EBITDA (%) (37,7)						
Profit after tax 1,479 1,405 1,610 1,720 1,730 Minority interests (73) (12) (127) (13) (13) Preferred dividends 1 <t< td=""><td></td><td>•</td><td>•</td><td>· ·</td><td>•</td><td></td></t<>		•	•	· ·	•	
Minority interests (73) (123) (127) (139) (158) Prefered dividends 1						
Preferred dividends 1 2 1 1 2 1 2 1 2 1 2 2 2 2 2 2		•				
Other items 1 2 1 2 1 2 <	•	-	(120)	(127)	(100)	(100)
Reported net profit 1,406 1,282 1,483 1,581 1,654 Non-recurring items & goodwill (net) 1,406 1,200 1,403 1,581 1,654 Recurring net profit 1,406 1,200 1,483 1,581 1,654 Recurring EPS 1,406 1,200 1,483 1,581 1,654 Recurring EPS 1,506 1,483 1,581 1,654 Recurring EPS 1,506 1,505 1,505 1,636 1,666		-	_	_	_	_
Non-recurring items & goodwill (net)		1.406	1,282	1.483	1.581	1.654
Per share (THB)		•		· ·		
Recurring EPS		1,406		1,483	1,581	1,654
Reported EPS	Per share (THB)					
D'S 0.50 0.50 0.40 0.40 0.38 Diluted shares (used to calculate per share data) 2,494 2,416 2,528 2,528 2,528	Recurring EPS *	0.56	0.48	0.59	0.63	0.66
Diluted shares (used to calculate per share data) 2,494	Reported EPS	0.56	0.51	0.59	0.63	0.66
Growth Revenue (%) (37.7) 0.0 6.4 6.0 5.4 Operating EBITDA (%) (44.6) (7.2) 16.5 6.9 6.3 Operating EBIT (%) (54.8) (13.7) 21.4 6.5 5.0 Recurring EPS (%) (53.7) (14.7) 23.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 6.6 4.6 Operating performance Cross margin inc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 38.9 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0	DPS	0.50	0.50	0.40	0.40	0.38
Revenue (%) (37.7)	Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Operating EBITDA (%) (44.6) (7.2) 16.5 6.9 6.3 Operating EBIT (%) (54.8) (13.7) 21.4 6.5 5.0 Recurring EPS (%) (53.7) (14.7) 23.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 6.6 4.6 Operating performance Gross margin inc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 38.9 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Inventory days 17.0 15.4	Growth					
Operating EBIT (%) (54.8) (13.7) 21.4 6.5 5.0 Recurring EPS (%) (53.7) (14.7) 23.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 6.6 4.6 Operating performance Gross margin inc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 38.9 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 <	Revenue (%)	(37.7)	0.0	6.4	6.0	5.4
Recurring EPS (%) (53.7) (14.7) 23.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 6.6 6.6 4.6 Reported EPS (%) (53.7) (8.8) 15.6 Reported EPS (%) (53.7) (8.8) 15.8 28.8 28.8 28.8 28.8 28.8 28.8 28.8 2	Operating EBITDA (%)	(44.6)	(7.2)	16.5	6.9	6.3
Reported EPS (%) (53.7) (8.8) 15.6 6.6 4.6 Operating performance Common to depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 30.8 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Divided payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Inventory days 17.0 <t< td=""><td>Operating EBIT (%)</td><td>(54.8)</td><td>(13.7)</td><td>21.4</td><td>6.5</td><td>5.0</td></t<>	Operating EBIT (%)	(54.8)	(13.7)	21.4	6.5	5.0
Operating performance Gross margin inc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 38.9 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROE (%) 10.9 10.0 11.9	Recurring EPS (%)	(53.7)	(14.7)	23.6	6.6	4.6
Gross margin inc. depreciation (%) 30.8 27.3 28.8 28.8 28.6 Gross margin exc. depreciation (%) 38.9 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 67.9 65.6 63.9 63.2 63.4 Creditor days 67.9 65.6 63.9 63.2 63.4 ROIC (%) 10.9 10.0 11.9 12.4 12.5 <td< td=""><td>Reported EPS (%)</td><td>(53.7)</td><td>(8.8)</td><td>15.6</td><td>6.6</td><td>4.6</td></td<>	Reported EPS (%)	(53.7)	(8.8)	15.6	6.6	4.6
Gross margin exc. depreciation (%) 38.9 35.8 37.5 37.6 37.7 Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROE (%)	Operating performance					
Operating EBITDA margin (%) 23.9 22.2 24.3 24.5 24.7 Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROE (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROE (%) 20.2 <t< td=""><td>Gross margin inc. depreciation (%)</td><td>30.8</td><td>27.3</td><td>28.8</td><td>28.8</td><td>28.6</td></t<>	Gross margin inc. depreciation (%)	30.8	27.3	28.8	28.8	28.6
Operating EBIT margin (%) 15.8 13.7 15.6 15.7 15.6 Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted	Gross margin exc. depreciation (%)	38.9	35.8	37.5	37.6	37.7
Net margin (%) 12.0 10.2 11.9 12.0 11.9 Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,	Operating EBITDA margin (%)	23.9	22.2	24.3	24.5	24.7
Effective tax rate (%) 21.5 20.7 20.0 20.0 20.0 Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889						
Dividend payout on recurring profit (%) 88.7 103.8 67.3 63.1 57.3 Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30	Net margin (%)					
Interest cover (X) 25.4 41.8 44.6 54.9 58.0 Inventory days 17.0 15.4 15.8 15.6 15.6 Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0 <td>• •</td> <td></td> <td></td> <td></td> <td></td> <td></td>	• •					
Inventory days						
Debtor days 37.0 27.2 26.6 25.1 23.8 Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted ** <	• •					
Creditor days 67.9 65.6 63.9 63.2 63.4 Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0						
Operating ROIC (%) 10.9 9.9 11.9 12.4 12.5 ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0						
ROIC (%) 10.9 10.0 11.9 12.4 12.5 ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0	•					
ROE (%) 11.2 9.4 11.2 11.5 11.5 ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0						
ROA (%) 8.2 7.7 9.3 9.5 9.6 * Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0	• •					
* Pre exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0						
Revenue by Division (THB m) 2023 2024 2025E 2026E 2027E Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0	• •	0.2	1.1	3.3	9.0	3.0
Cash patient revenue 7,976 7,930 8,281 8,748 9,191 SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0		-2022	2024	20255	2025	2027
SSO patient revenue 3,850 3,889 4,222 4,479 4,751 NHSO patient revenue (97) (93) (30) 0 0						
NHSO patient revenue (97) (93) (30) 0	•					
	•					
	NHSO patient revenue	(97)	(93)	(30)	U	Ü

Sources: Bangkok Chain Hospital; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027
Recurring net profit	1,406	1,200	1,483	1,581	1,65
Depreciation	944	998	1,083	1,167	1,26
associates & minorities	-	-	-	-	
Other non-cash items	114	465	117	139	15
Change in working capital	1,563	253	20	46	4:
cash flow from operations	4,027	2,916	2,704	2,932	3,117
Capex - maintenance Capex - new investment	(896)	(1,571)	(1,227)	(1,809)	(1,846
let acquisitions & disposals	4	(62)	0	0	
Other investments (net)	-	(02)	-	-	,
Cash flow from investing	(892)	(1,633)	(1,227)	(1,809)	(1,846
Dividends paid	(1,247)	(1,246)	(997)	(997)	(949
quity finance	0	0	0	0	(
Debt finance	(2,310)	(681)	0	0	
Other financing cash flows	(32)	(160)	(85)	(84)	(84
Cash flow from financing	(3,590)	(2,087)	(1,083)	(1,081)	(1,033
lon-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
let other adjustments	0	0	0	0	(
Novement in cash	(455)	(803)	395	42	23
ree cash flow to firm (FCFF)	3,230.18	1,338.18	1,532.13	1,174.49	1,322.7
ree cash flow to equity (FCFE)	791.94	442.79	1,392.14	1,039.81	1,187.3
er share (THB)					
CFF per share	1.30	0.54	0.61	0.47	0.5
CFE per share	0.32	0.18	0.56	0.42	0.4
Recurring cash flow per share	0.99	1.07	1.08	1.16	1.23
Balance Sheet (THB m) Year Ending Dec	2023	2024	2025E	2026E	20271
					00.04
angible fixed assets (gross)	20,884	23,120	24,356	26,165	28,01
ess: Accumulated depreciation	(8,639)	(10,287)	(11,370)	(12,537)	(13,803
angible fixed assets (net) ntangible fixed assets (net)	12,244 440	12,834 436	12,986 436	13,629 436	14,20 43
ong-term financial assets	440	430	430	430	40
vest. in associates & subsidiaries	28	90	90	90	g
Cash & equivalents	2,185	1,382	1,777	1,819	2,05
/C receivable	839	910	910	910	91
nventories	306	331	343	363	38
Other current assets	1,513	1,150	1,223	1,297	1,36
Current assets	4,843	3,773	4,252	4,389	4,71
Other assets	176	243	243	243	24
otal assets	17,731	17,375	18,007	18,786	19,69
Common equity	12,594	12,955	13,441	14,024	14,73
finorities etc.	1,110	1,072	1,113	1,169	1,23
otal shareholders' equity	13,704	14,027	14,554	15,193	15,96
ong term debt	1,497	324	324	324	32
Other long-term liabilities	187	203	203	203	20
ong-term liabilities	1,684	528	528	528	52
VC payable	1,368	1,340	1,388	1,469	1,54
Short term debt	81	573	573	573	57
Other current liabilities	894	907	965	1,023	1,07
Current liabilities	2,342	2,820	2,925	3,065	3,19
otal liabilities and shareholders' equity	17,731	17,375	18,007	18,786	19,69
let working capital	396	143	123	77	15.01
ivested capital Includes convertibles and preferred stock which is beir	13,284	13,746	13,878	14,475	15,01
·	ig trouted do dobt				
er share (THB)					
ook value per share	5.05	5.20	5.39	5.62	5.9
angible book value per share	4.87	5.02	5.22	5.45	5.7
inancial strength					
let debt/equity (%)	(4.4)	(3.5)	(6.0)	(6.1)	(7.3
let debt/total assets (%)	(3.4)	(2.8)	(4.9)	(4.9)	(5.9
current ratio (x)	2.1	1.3	1.5	1.4	1
F interest cover (x)	11.3	11.8	31.2	27.0	30.
aluation	2023	2024	2025E	2026E	2027
ecurring P/E (x) *	25.0	29.3	23.7	22.2	21
ecurring P/E @ target price (x) *	30.5	35.7	28.9	27.1	25
eported P/E (x)	25.0	27.4	23.7	22.2	21
vividend yield (%)	3.5	3.5	2.8	2.8	2
rice/book (x)	2.8	2.7	2.6	2.5	2
	2.9	2.8	2.7	2.6	2
rice/tangible book (x)					
rice/tangible book (x) V/EBITDA (x) **	12.7	13.7	11.7	10.9	10
		13.7 16.7	11.7 14.2	10.9 13.3	10 12

Sources: Bangkok Chain Hospital; FSSIA estimates

Bangkok Chain Hospital PCL (BCH TB)

FSSIA ESG rating

★ ★ ★

Exhibit 2: FSSIA ESG score implication

39.71 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Domesti	c ratings					Glo	bal ratings	;		Bloomberg	
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
вн	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	_	_	_	_	1	2
GHG scope 2 location-based	_	_	_	_	_	_	5	6
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	Yes						
Total energy consumption	_	_	_	_	_	_	10	12
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	10	12
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Yes
Hazardous waste	_	_	_	_	_	_	_	C
Total waste	_	_	_	_	_	_	_	C
Waste recycled	_	_	_	_	_	_	_	C
Waste sent to landfills	_	_	_	_	_	_	_	C
Environmental supply chain management	No	No	No	No	No	No	No	Yes
Water policy	No	No	No	No	No	No	Yes	Yes
Water consumption	_	_	_	_	_	_	_	_
Social								
Human rights policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	No	No	No	Yes
Quality assurance and recall policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	No	No	No
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	_	_	_	_	_	_	_	76
Pct disabled in workforce	_	_	_	_	_	_	_	
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Anti-bribery ethics policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Health and safety policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Lost time incident rate - employees	_	_	_	_	_	_	0	
Total recordable incident rate - employees	_	_	_	_	_	_	0	
Training policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Fair remuneration policy	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Number of employees – CSR	_	_	_	_	_	_	8,597	8,87
Employee turnover pct	_	_	_	_	_	_	_	4
Total hours spent by firm - employee training	_	_	_	_	_	_	_	54,70
Social supply chain management	No	Yes	Yes	Yes	Yes	Yes	Yes	Ye
Governance								
Board size	10	10	10	12	12	12	12	1.
No. of independent directors (ID)	4	4	4	4	4	4	4	
No. of women on board	3	3	3	4	4	3	3	;
No. of non-executive directors on board	5	5	5	5	5	5	5	
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ye
No. of board meetings for the year	6	5	6	5	5	6	6	
Board meeting attendance pct	93	94	90	96	100	99	94	9
Board duration (years)	_	_	_	_	_	_	_	_
Director share ownership guidelines	No	No	No	No	No	No	No	N
Age of the youngest director	28	29	30	29	30	31	32	3
Age of the oldest director	72	73	74	75	76	77	78	7
No. of executives / company managers	5	5	5	5	5	7	7	·
No. of female executives	1	_	_	_	_		· —	_
Executive share ownership guidelines	No	No	No	No	No	No	No	N
Size of audit committee	3	3	3	3	3	3	3	14
No. of ID on audit committee	3	3	3	3	3	3	3	
Audit committee meetings	4	4	5	5	5	5	5	
<u>~</u>	100	92	100	93	100	100	93	10
Audit meeting attendance % Size of compensation committee	0	0	0	0	0	0	93 0	10
-	U	U	U	U	U	U	U	,
No. of ID on compensation committee	_	_	_	_	_	_	_	_
No. of compensation committee meetings	_	_	_	_	_	_	_	_
Compensation meeting attendance %	_	_	_	_	_	_	_	_
Size of nomination committee	0	0	0	0	0	0	0	
No. of nomination committee meetings	_	_	_	_	_	_	_	_
Nomination meeting attendance %	_	_	_	_	_	_	_	_
Sustainability governance								

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the anr Only the top inclusion.	ed on the com nual S&P Glob -ranked comp	transparent, rules-based npanies' Total Sustainabili oal Corporate Sustainabilit nanies within each industry	ity Scores resulting y Assessment (CSA). y are selected for	Sustainability A ESG Score of I scoring compar selected from the	ssessment (C ess than 45% ny are disqual ne Eligible Un		mpanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing be Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders come key disq ependent direct related to CG	onsibility in Environmental ransparency in Governance preemptive criteria, with he board members and ex- s, and combined holding in jualifying criteria include: 1 ctors and free float violation, social & environmental in parnings in red for > 3 year	ce, updated annually. two crucial conditions: tecutives; and 2) free nust be >15% of paid-) CG score of below in; 3) executives' impacts; 4) equity in	minimum of 500 during the assenature of the research 1) market capit liquidity >0.5% SETTHSI Index	% for each ind ssment year. levant industr is extended falization > TH of paid-up cap is a market of	iclusion, verified licator, unless the The scoring will by and materiality. From the SET ES B5b (~USD150b) bital for at least 9 apitalisation-weig, and no cap for i	e company is a pe fairly weigh G Ratings core; 2) free float out of 12 more ghted index, c	a part of DJSI ated against the against the apanies whose >20%; and 3) aths. The ap 5%
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (St	the Thai IOD,	th in sustainable developn with support from the Sto Its are from the perspectiv is.	ck Exchange of	Good (80-89), 3 and not rated for equitable treatr	B for Good (70 or scores belo nent of shareh 5%); 4) disclo	ories: 5 for Excell 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), the rights; 2) and (); 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiabilit	e incorporated and sufficientla e CG compor r AGM proced and after the sufficient informa e second assess y; and 3) openne	which shareholders' rights d into business operations by disclosed. All form imponents to be evaluated annutures before the meeting (meeting (10%). (The first astation for voting; and 2) facilitating the ease of attending meess for Q&A. The third involveues, resolutions and voting res	s and information is rtant elements of two ually. The assessment 45%), at the meeting ssesses 1) advance ing how voting rights can be eetings; 2) transparency is the meeting minutes that			four categories: (80-89), and not		
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key control c Certification deciding to become Intent to kick offi ncluding risk ass demployees, est	Checklist include corruption of the control of the	art by submitting a mit the CAC Checklist for a control, training of	passed Checkli	st will move for se members a	ed by a committe or granting certific re twelve highly r chievements.	cation by the C	CAC Council
Morningstar Sustainalytics	based on an risk is unma regulatory filin	assessment naged. Source gs, news and ot	isk rating provides an ove of how much of a compan is to be reviewed include corpo ther media, NGO reports/webs ck, ESG controversies, issuer i	ny's exposure to ESG orate publications and orites, multi-sector			score is the sum higher ESG risk Medium		ed risk. The
		uality & peer rev		eedback on drait LSG	0-10	10-20	20-30	30-40	40+
ESG Book	positioned to the principle helps explai over-weighti	o outperform o of financial m n future risk-a	sustainable companies the over the long term. The me nateriality including informa djusted performance. Mat ith higher materiality and it erly basis.	ethodology considers ation that significantly eriality is applied by	The total ESG scores using m	score is calcul ateriality-base	ated as a weighted weights. The s	ed sum of the core is scaled	features
<u>MSCI</u>			measure a company's ma nd laggards according to						nethodology to
	AAA	8.571-10.00	00 Leader:	leading its industry in ma	anaging the most si	anificant ESC ri	eke and apportunition	ne.	
	AA	7.143-8.570		reading its industry in the	anaging the most si	griincant 200 m	and opportunite		
	Α	5.714-7.142	2						
	BBB	4.286-5.713	3 Average:	a mixed or unexceptional industry peers	ii irack record of ma	anaging the mos	a significant ESG ris	sks and opportur	illies relative to
	ВВ	2.857-4.28	5						
	В	1.429-2.856	6 Laggard:	lagging its industry base	d on its high expos	ure and failure to	o manage significan	t ESG risks	
	CCC	0.000-1.428	88	. 55 9 340 5400			ggouii		
Moody's ESG solutions	believes tha	t a company ii	gree to which companies t integrating ESG factors int for shareholders over the r	o its business model and					
Refinitiv ESG rating	based on pu	blicly available	and objectively measure le and auditable data. The ata publicly. (Score ratings a	score ranges from 0 to 1	00 on relative E	SG performar	ice and insufficie	nt degree of ti	
S&P Global			ore is a relative score mea nin the same industry clas				of ESG risks, opp	oortunities, an	d impacts
Bloomberg	ESG Score		score is based on Bloom	ating the company's aggr nberg's view of ESG fina the weights are determin	ncial materiality.	The score is	a weighted gener	alized mean (power mean)

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Vatcharut Vacharawongsith FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
25-Oct-2022 09-Feb-2023 03-May-2023 03-Aug-2023	BUY BUY BUY BUY	26.00 25.50 23.50 22.50	03-Nov-2023 30-Jan-2024 29-Apr-2024 30-Jul-2024	BUY BUY BUY BUY	24.50 26.00 25.00 22.00	31-Oct-2024 31-Jan-2025 17-Jul-2025	BUY BUY BUY	21.00 20.00 17.20

Vatcharut Vacharawongsith started covering this stock from 17-Jul-2025

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	всн тв	THB 14.10	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 14-Aug-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.